Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 24 January 2017, 17:43 HKT/SGT

Source: Eisai
Eisai Selected for Excellence in Sustainability Performance and Industry Mover Distinction by Robecosam

TOKYO, Jan 24, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for excellence in sustainability performance by RobecoSAM AG, a leading assessor of Social Responsibility Investment (SRI). Eisai has also been selected for the Industry Mover distinction in the pharmaceutical industry category, for achieving the
largest proportional improvement in its sustainability performance compared to the previous year.

Every year, RobecoSAM assesses major companies from around the world based on economic, environmental and social criteria. The top companies are showcased in The Sustainability Yearbook, an important indicator of environmental, social and governance (ESG) performance. This year, 2,473 companies from 60 industries were assessed. In each industry, companies that fall in the top 15%, and have scored at least 70% of the industry's top performing company's score, are selected for excellence in sustainability performance. Within the pharmaceutical industry category, 62 global companies were assessed, and 12 companies, including Eisai, were selected for excellence in sustainability performance.

In addition, Eisai has been selected for membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), as well as the FTSE4Good Index Series. Both are families of premier global indices for SRI.

The Eisai Group's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Guided by this philosophy, Eisai will continue to develop innovative new drugs and make them available to patients around the world as early as possible to fulfill its social responsibility and secure the trust of stakeholders.

About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit

Public Relations Department,
Eisai Co., Ltd.

Jan 24, 2017 17:43 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: HealthCare
From the Asia Corporate News Network

Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Apr 19, 2017 12:21 HKT/SGT
Eisai Announces Results and Continued Support of Initiatives for Elimination of Lymphatic Filariasis
Apr 11, 2017 11:42 HKT/SGT
Eisai to Launch "Chocola BB Gold Rich" Highest Combination of Active Ingredients in Chocola BB Series
Apr 5, 2017 10:23 HKT/SGT
Eisai and Meiji Enter Into Licensing Agreement Concerning Parkinson's Disease Drug Safinamide in Japan and Asia
Apr 5, 2017 10:12 HKT/SGT
Eisai Presents Data of Mechanisms of Action Relating to Tumor Immune Response Regarding Combination of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody at AACR 108th Annual Meeting
Apr 4, 2017 08:56 HKT/SGT
Eisai to Launch Smell Identification Test UPSIT Series in Japan
Mar 29, 2017 10:09 HKT/SGT
Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan
Mar 29, 2017 09:08 HKT/SGT
German Federal Joint Committee (G-Ba) Confirms Additional Benefit of Anticancer Agent Kisplyx (Lenvatinib Mesylate) in Treatment of Advanced Renal Cell Carcinoma
Jan 25, 2017 07:59 HKT/SGT
Phase III Trial of Anticancer Agent Lenvima as First-Line Treatment for Unresectable Hepatocellular Carcinoma Meets Primary Endpoint
Jan 18, 2017 13:23 HKT/SGT
Eisai to Participate in Access Accelerated, Global Partnership to Address Rise of Non-Communicable Diseases
Jan 16, 2017 08:19 HKT/SGT
Transfer of Rights to Insomia Treatment / Anaesthesia Induction Agent Flunitrazepam in Japan
More news >>
 News Alerts
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: